Fig. 1: SSRI and placebo response rates. | Translational Psychiatry

Fig. 1: SSRI and placebo response rates.

From: Impact of chosen cutoff on response rate differences between selective serotonin reuptake inhibitors and placebo

Fig. 1

Cumulative proportions of SSRI- and placebo-treated patients scoring on or below each 5% fraction of baseline scores at endpoint are shown for HDRS-17-sum in a and for HDRS-6-sum in b. Cumulative proportions of SSRI- and placebo-treated patients reporting different score reductions with respect to depressed mood are shown in c. Corresponding data but for each endpoint score are displayed in d (HDRS-17-sum), e (HDRS-6) and f depressed mood. Shown is the ITT-LOCF population. n = 5424 (SSRI) and 2485 (placebo). Patients deteriorating during treatment were coded as having an endpoint fraction of 100% a–b or a change score of zero c. The share of patients deteriorating was a SSRIs 8.8%; placebo 12.4%, b SSRIs 7.4%; placebo 11.9%, c SSRIs 3.7%; placebo 7.0%. Endpoint scores were capped at 40 points (d) and 20 points (e), respectively. The share of patients scoring above these thresholds was d SSRIs 0.13%, placebo 0.04%, e SSRIs 0.02%, placebo 0.00%.

Back to article page